Login / Register

Whole Site News Feeds P&T Journal

Announcing... the Redesigned Managed Care Magazine Website

Life is change. At Managed Care, we are breathing new life into our website by changing its look, but not only the look. Our home page is now a blog, and will feature short, pointed, readable articles by a varied group of contributors—people from many areas of health care, from present and former health plan medical directors to pharmacy experts, practicing physicians, consumer and employer advocates and representatives, and people active in many other sectors of health care.

Visit the new Managed Care Website and add your voice to the discussion.

View the new or updated Formulary Kits for Onglyza, Samsca, Viibryd, and Xarelto.

Pharmacy Policies/Procedures: Forms and guidelines

Cost Calculators: Exclusive online tools to evaluate your pharmacy costs

Links: A comprehensive map of web links to the world of managed care pharmacy

• Elevated Risk Factors Linked to Major Cardiovascular Disease Events Across a Lifetime
• CT Scans for Dizziness in the ER: Worth the cost?
• CAP Guidelines Available Online
• First Test for Brain Infection Associated With Tysabri Cleared for Marketing
• Subcutaneous Velcade Gains FDA Nod

News by category
• FDA Updates
• Drug Trials and Comparisons
• Managed Pharmacy Trends
• Legislation and Policy

Digital Edition

• Web-based
• Free to all
• All the words and pictures of the print edition
• Searchable
• Can be downloaded to read offline

• Register for a free digital subscription
• Preview the digital edition

Archive issues of P&T Journal:

• January 2011
• February 2011
• March 2011
• April 2011
• May 2011
• June 2011
• July 2011
• August 2011
• September 2011
• October 2011
• November 2011

Immunotherapy for Advanced Prostate Cancer: A Novel Treatment Option to Improve Survival

Prostate cancer is the second leading cause of cancer death in men in the United States. Sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved by the U. S. Food and Drug Administration, improves survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant (hormone refractory) prostate cancer. This Clinical Brief discusses the epidemiology, natural history, and risk factors for prostate cancer, current diagnosis and treatment modalities, and the emergence of immunotherapy as a novel treatment to improve survival in men with advanced disease. Roger Muller, MD, FACEP, comments on managed care considerations. Safety information and full prescribing information for Sipuleucel-T are also provided.

Comparative Effectiveness Research: Paving the Way for Evidence-Based Decision Making

The second in a series of topics of interest for the managed care community, this brief details the background of comparative effectiveness research (CER) in the United States and discusses the goals versus the uses of CER and the importance of collecting real-world data to support evidence-based medicine. Included are examples of the effective use of CER in clinical practice.

Visit Formkit.com to view the newest formulary kits, now available online:

BRILINTA^™(ticagrelor) tablets
Please click for full Prescribing Information, including Boxed Warnings, and Medication Guide

KOMBIGLYZE^™ XR (saxagliptin and metformin HCl extended-release) tablets
Please click for full Prescribing Information, including Boxed Warnings, and Medication Guide
NEW FORMULARY KIT

LYRICA^® (pregabalin)
NEW FORMULARY KIT

Onglyza (saxagliptin) UPDATED FORMULARY KIT

Privigen (Immune Globulin Intravenous [Human], 10% Liquid)

Provenge (sipuleucel-T)

SAMSCA® (tolvaptan) UPDATED FORMULARY KIT

VIIBRYD® (vilazodone HCl)
Please click here for US Full Prescribing Information
NEW FORMULARY KIT

XARELTO® (rivaroxaban tablets)
Please click here for US Full Prescribing Information
UPDATED FORMULARY KIT

January 2012